PLK Targeted Therapies Market By Drug Type (PLK1 Inhibitors, Multi-Kinase Inhibitors); By Cancer Indication (Acute Myeloid Leukemia, Prostate Cancer, Ovarian Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Other Indications Led by Colorectal Cancer); By Treatment Line (First-Line Therapy, Second-Line Therapy, Maintenance and Combination Therapy); By Therapy Approach (Monotherapy, Combination Therapy, Biomarker-Guided Therapy); By End User (Hospitals, Specialty Oncology Clinics, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

PLK Targeted Therapies Market - Selective PLK Programs Move the Market Toward Its First Commercial Validation

The PLK targeted therapies market remains an emerging clinical-stage market rather than an established prescription category. No direct PLK inhibitor was identified as commercially approved in the reviewed regulatory, company, and clinical-trial evidence as of July 2026. Leading assets such as onvansertib, ocifisertib, RP-1664, plogosertib, and BAL0891 remain investigational. Cardiff Oncology also states that it has not commercially marketed, distributed, or sold a product candidate. The current market valuation therefore measures clinical-development value, prospective product revenue, licensing potential, pipeline investment, and future indication opportunities rather than existing audited sales of approved PLK drugs.

 

Onvansertib Creates the First Credible Registrational Route for PLK1 Inhibition

Cardiff Oncology’s onvansertib is the most advanced visible selective PLK1 inhibitor and currently represents the market’s largest near-term commercial catalyst. The company’s CRDF-004 randomized Phase 2 study enrolled 110 patients with previously untreated RAS-mutated metastatic colorectal cancer and evaluated onvansertib with FOLFIRI/bevacizumab or FOLFOX/bevacizumab against the corresponding standard-of-care regimens.

At the March 18, 2026 data cut, the selected 30 mg onvansertib plus FOLFIRI/bevacizumab arm produced a confirmed objective response rate of 72.2%, representing 13 of 18 patients, compared with 42.1%, or 8 of 19 patients, receiving FOLFIRI/bevacizumab alone. The trial also reported a blinded independent central review progression-free survival hazard ratio of 0.55, although the confidence interval remained wide because of the small number of patients. Cardiff subsequently completed an End-of-Phase 2 meeting with the FDA and aligned on a randomized Phase 3 design comparing onvansertib plus FOLFIRI/bevacizumab with FOLFIRI/bevacizumab alone. The company’s July 2026 presentation indicated that initiation of the Phase 3 registrational program was planned for the second half of 2026.

The lead program is commercially important because it targets first-line treatment rather than a small salvage population. Cardiff has previously estimated that approximately 48,000 new patients annually in the United States enter the first-line RAS-mutated metastatic colorectal cancer setting. The estimate is not equivalent to a reimbursed or treated-patient count, but it is the strongest publicly available population measure for the market’s most advanced PLK program.

Cardiff is also supporting investigator-led studies of onvansertib in metastatic pancreatic ductal adenocarcinoma, relapsed small-cell lung cancer, metastatic triple-negative breast cancer, and chronic myelomonocytic leukemia. These programs expand the asset’s licensing and lifecycle potential, but colorectal cancer remains the primary value driver because it has randomized evidence and a defined registrational route.

 

The Pipeline Contains Multiple Studies but a Limited Number of Distinct Clinical Assets

The PLK pipeline appears broad when counted by clinical studies, indications, and combination arms. The number of distinct clinical-stage molecules is considerably smaller. The reviewed public pipeline identifies five principal active or recently active direct and materially PLK-targeting candidates: onvansertib, plogosertib, ocifisertib, RP-1664, and BAL0891.

This concentration has two commercial effects. A successful pivotal study could allow one developer to establish an early dominant position because there is no approved class competitor. Conversely, a major safety failure, financing interruption, or negative registrational result could materially reduce investor support across the entire mechanism.

 

Ocifisertib Builds the Broadest PLK4 Trial Network

Treadwell Therapeutics is developing ocifisertib, previously known as CFI-400945, as an oral PLK4 inhibitor. Its public pipeline lists six PLK4 studies covering AML, myelodysplastic syndromes, chronic myelomonocytic leukemia, advanced breast cancer, triple-negative breast cancer, prostate cancer, and other advanced solid tumors.

The TWT-202 Phase 1/2 program is evaluating ocifisertib alone and with azacitidine or decitabine in AML, MDS, and CMML. Additional Phase 1/2 studies assess monotherapy in advanced breast cancer, combination treatment with durvalumab in triple-negative breast cancer, and a biomarker-enriched prostate cancer strategy. Two earlier monotherapy dose-escalation studies in advanced solid tumors and relapsed or refractory AML or MDS remain listed as active but not recruiting.

The FDA granted orphan-drug designation to ocifisertib for AML in February 2024, adding to its earlier Fast Track designation. These designations can support closer regulatory interaction and orphan-market economics, but the drug still requires stronger response-duration, survival, and safety evidence before its specialist hematology opportunity can be translated into commercial revenue.

Treadwell’s multiple studies explain why PLK4 deserves a separate drug-type segment. Ocifisertib is a selective PLK4 inhibitor, not a general multi-kinase product, and grouping it with pan-kinase compounds would distort the competitive structure of the market.

 

RP-1664 Connects PLK4 Inhibition with Synthetic-Lethality Development

RP-1664 represents a second, more biomarker-focused PLK4 strategy. Repare Therapeutics designed the oral inhibitor around the synthetic-lethal relationship between PLK4 inhibition and TRIM37 amplification or overexpression.

Repare completed enrollment of 29 adult and adolescent patients in the Phase 1 LIONS study evaluating RP-1664 as monotherapy in TRIM37-high solid tumors. The company subsequently reported positive initial safety, tolerability, and early efficacy findings at the 2025 AACR-NCI-EORTC conference, stating that the results supported further evaluation in molecularly selected, tumor-specific cohorts and potentially in less heavily pretreated patients.

The opportunity is particularly relevant to high-risk neuroblastoma. Repare has reported that elevated TRIM37 is present in approximately 80% of high-grade neuroblastoma, while 2025 preclinical research found substantial activity for RP-1664 across TRIM37-high and neuroblastoma models. The biomarker creates a concentrated development strategy but also makes commercial scale dependent on reliable TRIM37 testing and confirmation that the early activity translates into durable patient responses.

Repare agreed to be acquired by XenoTherapeutics in a transaction announced in November 2025. The transaction and continuing portfolio-monetization process introduce uncertainty regarding the pace, funding, ownership, and partnering route for RP-1664, even though the asset remains one of the few selective PLK4 inhibitors to have entered clinical development.

 

Plogosertib Preserves a Second Selective PLK1 Development Route

Plogosertib, also known as CYC140, is an oral selective PLK1 inhibitor being studied in the registered Phase 1/2 trial NCT05358379 for advanced solid tumors and lymphoma. The program includes dose escalation and potential expansion cohorts intended to identify responsive tumor populations after standard therapy.

Plogosertib remains behind onvansertib in clinical maturity and lacks a comparable randomized registrational signal. Its commercial importance lies in maintaining competition within selective PLK1 inhibition and providing an alternative asset for leukemia, lymphoma, colorectal cancer, and other solid-tumor development. Preclinical research published in 2025 also continued to examine plogosertib in colorectal and biliary tract cancer models, supporting indication-selection work rather than immediate commercial demand.

 

BAL0891 Establishes a Commercial Role for Dual-Kinase Inhibition

BAL0891 expands the market beyond highly selective single-target agents. The molecule inhibits both TTK and PLK1 and is being evaluated in the Phase 1 NCT05768932 study in advanced solid tumors and relapsed or refractory AML. The study includes monotherapy and combination-development pathways, while current sponsor information describes the program as being in dose escalation.

The dual mechanism differentiates BAL0891 from onvansertib and plogosertib. Its commercial positioning will depend on whether combined TTK and PLK1 inhibition provides a wider therapeutic window than earlier pan-PLK compounds. Phase 1 results presented at ASCO 2026 provide an initial clinical evidence point, while the larger development strategy includes AML, breast cancer, and other solid tumors.

BAL0891 gives the multi-kinase segment a current clinical asset, but this category remains smaller than selective PLK1 and PLK4 development because wider kinase activity can increase dose-limiting toxicity and complicate attribution of clinical benefit.

 

Historical Class Failures Raise the Value of Selectivity

Earlier PLK programs demonstrate that target relevance alone is insufficient to create a successful oncology product. Volasertib advanced into Phase 3 AML development but failed its primary endpoint and produced an unfavorable survival trend associated with safety. Other earlier PLK1 inhibitors, including BI 2536 and GSK461364, did not establish commercial products.

These outcomes shifted development toward oral agents, intermittent dosing, stronger target selectivity, combination regimens, and biomarker-defined populations. They also increased the amount of safety and comparative-efficacy evidence that regulators, investors, oncologists, and payers are likely to require from current programs.

 

Biomarker Selection Changes the Obtainable Patient Population

The current pipeline is moving away from broad PLK expression as the primary basis for treatment. Onvansertib is being advanced in RAS-mutated colorectal cancer, RP-1664 is linked to TRIM37-high tumors, and ocifisertib studies incorporate tumor-specific and biomarker-enrichment strategies.

This approach can improve clinical-trial efficiency and produce a stronger reimbursement argument because the product is directed toward patients with a defined biological vulnerability. It also reduces the commercially obtainable population. Tissue availability, sequencing rates, assay validation, result turnaround time, treatment-line eligibility, patient fitness, and payer authorization create losses between total cancer incidence and actual PLK prescriptions.

The diagnostic infrastructure is relatively favorable in metastatic colorectal cancer because RAS testing is already routinely used to guide treatment. TRIM37 selection is less established and may require a dedicated assay-development and physician-education pathway before a PLK4 product can achieve broad commercial adoption.

 

PLK1 Inhibitors Hold the Largest Drug-Type Revenue Share

The original drug-type segmentation has been expanded to include PLK4 inhibitors as a separate category. This correction is necessary because ocifisertib and RP-1664 selectively target PLK4 and should not be classified as multi-kinase inhibitors.

PLK1 inhibitors are estimated to account for 68% of the market in 2025, representing approximately USD 809 million. The segment is projected to reach nearly USD 1.48 billion by 2032, when its market share is expected to rise to 70%. This translates into a segment CAGR of approximately 9.0%. Onvansertib’s Phase 3 transition, first-line colorectal positioning, and additional investigator-sponsored programs make PLK1 inhibition the largest source of modeled revenue.

PLK4 inhibitors are estimated to represent 20% of the market in 2025, equal to approximately USD 238 million. Their value is forecast to rise to nearly USD 485 million by 2032, increasing the segment share to 23% and producing the fastest drug-type CAGR of approximately 10.7%. Growth is supported by ocifisertib’s six-study footprint and RP-1664’s biomarker-focused synthetic-lethality strategy.

Multi-kinase and pan-PLK inhibitors are estimated to generate approximately USD 143 million in 2025, representing 12% of the market. The segment is projected to reach nearly USD 148 million by 2032, while its share declines to 7% and its CAGR remains close to 0.5%. BAL0891 provides an active dual TTK/PLK1 opportunity, but historical safety limitations associated with less-selective PLK programs constrain the wider category.

 

Colorectal Cancer Becomes the Largest Indication Opportunity

Colorectal cancer is estimated to account for 28% of the market in 2025, equivalent to approximately USD 333 million. The segment is forecast to reach nearly USD 781 million by 2032, increasing its share to 37% and registering the fastest indication CAGR of approximately 12.9%. Growth is primarily linked to onvansertib in first-line RAS-mutated metastatic colorectal cancer.

Acute myeloid leukemia is estimated to generate approximately USD 286 million in 2025, representing 24% of the market. The segment is projected to reach around USD 422 million by 2032, although its share decreases to 20% as solid-tumor programs move toward later development. The resulting AML segment CAGR is approximately 5.7%. Ocifisertib, BAL0891, and historical PLK development activity make AML one of the largest clinical research areas for the class.

Breast cancer is estimated at approximately USD 131 million in 2025, representing 11% of the market. Revenue is projected to increase to nearly USD 211 million by 2032, equal to 10% of the market and a CAGR of approximately 7.1%. The opportunity includes ocifisertib monotherapy, its durvalumab combination in triple-negative breast cancer, onvansertib investigator research, and possible BAL0891 development.

Prostate cancer is estimated to represent 11% of the market in 2025, or approximately USD 131 million. It is forecast to reach around USD 190 million by 2032, when its share falls to 9%, resulting in a CAGR of approximately 5.5%. Development remains concentrated on early PLK4 studies in metastatic castration-resistant disease.

Ovarian cancer is estimated to generate approximately USD 107 million in 2025, accounting for 9% of the market. Its value is projected to rise to approximately USD 169 million by 2032, representing 8% of the total and a CAGR of nearly 6.7%. Commercial progress depends on identifying ovarian tumors in which PLK inhibition adds value to DNA-damage response therapies, chemotherapy, or other targeted combinations.

Non-small-cell lung cancer is estimated to account for approximately USD 95 million in 2025, equivalent to 8% of the market. The segment is projected to reach nearly USD 169 million by 2032, retaining an 8% share and expanding at approximately 8.5% annually. Most of the current PLK lung-cancer activity remains preclinical or early clinical, making biomarker identification central to future investment.

Other solid and hematological indications are estimated at approximately USD 107 million in 2025 and USD 169 million by 2032. This category represents 9% of the market in 2025 and 8% in 2032, with a CAGR of approximately 6.7%. It includes pancreatic cancer, small-cell lung cancer, neuroblastoma, CMML, lymphoma, and other TRIM37-high or PLK-dependent tumors.

 

First-Line Therapy Records the Strongest Commercial Expansion

Second-line therapy is estimated to hold the largest line-of-therapy share in 2025 at 39%, representing approximately USD 464 million. It is projected to reach around USD 633 million by 2032, but its share declines to 30% and its CAGR remains approximately 4.5%. Investigational oncology products frequently begin in relapsed or refractory populations because those patients have fewer alternatives and a lower evidence barrier than untreated disease.

First-line therapy is estimated to account for 33% of the market in 2025, equal to approximately USD 393 million. The segment is forecast to become the largest by 2032, reaching approximately USD 907 million, increasing its share to 43%, and expanding at a CAGR of nearly 12.7%. Onvansertib’s first-line colorectal program is the principal reason for this shift.

Maintenance and combination therapy is estimated to generate approximately USD 333 million in 2025, representing 28% of the market. It is projected to reach approximately USD 570 million by 2032, equal to 27% of the market and a CAGR of nearly 8.0%. PLK products are increasingly being developed with chemotherapy, bevacizumab, hypomethylating agents, immune checkpoint inhibitors, or other targeted drugs rather than as stand-alone replacements for established therapy.

 

North America Leads While Asia-Pacific Records the Fastest Regional Growth

North America is estimated to account for 45% of global market value in 2025, representing approximately USD 536 million. The region is projected to reach approximately USD 907 million by 2032, retaining the leading position with a 43% share and a CAGR of approximately 7.8%. The United States contains the most advanced PLK1 registrational pathway, major oncology trial centers, molecular-testing infrastructure, specialist biotechnology developers, and the largest immediate financing and partnering market.

Europe is estimated to represent 27% of the market in 2025, equal to approximately USD 321 million. Its value is forecast to rise to nearly USD 528 million by 2032, when the region accounts for 25% of global revenue and expands at approximately 7.3% annually. Strong clinical-research capacity supports development, although country-level pricing and reimbursement decisions may produce uneven commercial uptake.

Asia-Pacific is estimated at approximately USD 238 million in 2025, representing 20% of the market. It is projected to reach nearly USD 506 million by 2032, increasing its share to 24% and recording the fastest regional CAGR of approximately 11.4%. Growth will come from rising oncology trial participation, expansion of genomic testing, larger treated cancer populations, and increasing adoption of targeted therapies in China, Japan, South Korea, Australia, and other major regional markets.

Latin America is estimated to account for 5% of the market in both 2025 and 2032. Regional revenue is forecast to rise from approximately USD 60 million to USD 106 million, representing a CAGR of approximately 8.5%. Adoption will depend on regulatory sequencing, private oncology channels, and access to biomarker testing.

The Middle East and Africa are estimated to represent 3% of global market value, increasing from approximately USD 36 million in 2025 to USD 63 million by 2032. The implied CAGR is approximately 8.5%, although commercial demand will remain concentrated in higher-income healthcare systems and specialist oncology centers.

 

Financing and Asset Control Remain Commercial Variables

PLK development requires substantial financing because the market has no approved product revenue to fund late-stage trials. Cardiff reported USD 46.1 million in cash, cash equivalents, and short-term investments as of March 31, 2026 and stated that the balance was insufficient to meet its funding requirements for at least the following 12 months. The company subsequently completed a registered direct offering with gross proceeds of approximately USD 10.05 million in July 2026.

Cardiff is also disputing an allegation by Nerviano Medical Sciences that it breached the onvansertib license agreement. The disagreement concerns ownership and patent matters associated with methods of using onvansertib with bevacizumab in metastatic colorectal cancer. The dispute introduces a material asset-control risk because onvansertib accounts for the largest share of the near-term PLK opportunity.

RP-1664 faces a different form of strategic uncertainty following Repare’s acquisition agreement with XenoTherapeutics. The asset’s future value may be realized through continued internal development, licensing, portfolio sale, or a partnership capable of financing tumor-specific expansion studies.

 

Strategic Market Outlook

The market’s principal growth mechanism is the transition of PLK inhibition from broad, toxicity-limited cell-cycle targeting to selective and biomarker-guided oncology development.

Onvansertib provides the nearest potential commercial inflection point. A successful Phase 3 study in first-line RAS-mutated metastatic colorectal cancer could establish the first direct PLK price, reimbursed treatment population, prescription base, and commercial benchmark. It would also increase the licensing value of earlier PLK1, PLK4, and dual-kinase programs.

Ocifisertib and RP-1664 provide a second growth route through selective PLK4 inhibition. Ocifisertib offers broad indication diversification, while RP-1664 offers a narrower synthetic-lethality strategy tied to TRIM37-high tumors. Plogosertib maintains competition within PLK1 inhibition, and BAL0891 provides a distinct dual TTK/PLK1 approach.

The market remains exposed to pivotal-trial failure, hematological and mitotic toxicity, biomarker-access limitations, intellectual-property disputes, financing pressure, and competition from established targeted drugs, antibody-drug conjugates, immunotherapies, and DNA-damage response agents.

Under the Strategic Market Research forecast, the strongest incremental revenue is expected from selective PLK1 and PLK4 inhibitors, colorectal cancer, first-line treatment, combination regimens, and Asia-Pacific expansion. The projected increase from USD 1.19 billion in 2025 to USD 2.11 billion by 2032 will ultimately depend on clinical validation and reimbursement acceptance rather than broad cancer incidence or the number of registered pipeline trials alone.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
By Drug Type	PLK1 Inhibitors; Multi-Kinase Inhibitors
By Cancer Indication	Acute Myeloid Leukemia; Prostate Cancer; Ovarian Cancer; Breast Cancer; Non-Small Cell Lung Cancer; Other Indications Led by Colorectal Cancer
By Treatment Line	First-Line Therapy; Second-Line Therapy; Maintenance and Combination Therapy
By Therapy Approach	Monotherapy; Combination Therapy; Biomarker-Guided Therapy
By End User	Hospitals; Specialty Oncology Clinics; Research Institutes; Academic Medical Centers
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Advancement of Selective PLK Inhibitors	Progress of selective PLK1 and PLK4 inhibitors through clinical trials is creating a pathway toward potential commercialization and oncology adoption.
Market Drivers – Biomarker-Guided Precision Oncology	Increasing focus on molecular patient selection, including RAS-mutated and TRIM37-high populations, is improving clinical targeting and development efficiency.
Market Drivers – Combination Therapy Opportunities	Integration of PLK inhibitors with chemotherapy, targeted therapies, and other oncology regimens is expanding potential treatment applications.
Customization Option	Available upon request